Please login to the form below

Not currently logged in
Email:
Password:

Momenta

This page shows the latest Momenta news and features for those working in and with pharma, biotech and healthcare.

Biogen takes on Lucentis, Eylea biosimilars from Samsung joint venture

Biogen takes on Lucentis, Eylea biosimilars from Samsung joint venture

Alteogen and Momenta/Mylan have versions of Eylea in development, while Coherus and Xbrane Pharma are among companies which are working on Lucentis biosimilars.

Latest news

More from news
Approximately 3 fully matching, plus 15 partially matching documents found.

Latest Intelligence

  • Building a bright future Building a bright future

    Mylan’s biosimilar of the multiple sclerosis injection therapy copaxane is not gliding to the promised land, and delays have given rivals Momenta and Novartis’ Sandoz a tilt at the

  • Deal Watch January 2017 Deal Watch January 2017

    625. Momenta. CSL. Licence. M230 immuno-modulator of Fc receptors. 600. ImmuNext.

  • Deal Watch January 2016 Deal Watch January 2016

    255. Mylan/ Momenta. Co-development, co-commercialisation . Exclusive global collaboration with Momenta for 6 biosimilars including a biosimilar version of Orencia (abatacept)  . 245. Athersys/ Healios. Licence. Development and commercialisation

  • Modern anticoagulants threaten status quo Modern anticoagulants threaten status quo

    The LMWH pipeline includes three compounds: certoparin sodium (Embolex; Novartis), semuloparin (Visamerin; Sanofi) and adomiparin (Momenta Pharmaceuticals).

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hanover Communications

Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics